Navigation Links
New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation
Date:7/6/2009

ROCKVILLE, Md., July 6 /PRNewswire-USNewswire/ -- A procedure that sends targeted energy into the heart through a catheter can be used to treat a common type of irregular heartbeat, but little is known about the treatment's long-term benefits and the best methods and circumstances for applying it, according to a new report funded by HHS' Agency for Healthcare Research and Quality.

The report examines the use of a procedure called radiofrequency catheter ablation to treat a type of irregular heartbeat known as atrial fibrillation. The new comparative effectiveness report found that the procedure has been shown to provide benefits in maintaining normal heart rhythm over short periods of time (up to 1 year) but found little evidence indicating whether the procedure reduces the chance that patients will experience atrial fibrillation over the long term.

The report, which compared radiofrequency catheter ablation to medication-based therapy, also found that the effect of the procedure on stroke, a major risk for patients with atrial fibrillation, is unknown. Radiofrequency catheter ablation - a procedure in which a long, thin, flexible tube is put through a blood vessel into the heart - often is used when medications do not work. In this procedure, energy pulses are delivered through the catheter to the heart, destroying small areas of heart tissue where abnormal electrical signals may cause an arrhythmia to start.

Different techniques and instruments can be used for the procedure. While there is no strong evidence to suggest that one particular technique is best for any given patient, there is general consensus concerning a basic approach to ablation procedures for atrial fibrillation. In addition, there is little evidence indicating the procedure's effectiveness when used as a first-line therapy instead of medication.

"Radiofrequency holds promise for treating atrial fibrillation, but it is cl
'/>"/>

SOURCE Agency for Healthcare Research & Quality
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)..., Nov. 6 Caraco Pharmace...aunched ketorolac tromethamine ophthalmic solution... and Drug Administration (FDA) for Sun Pharma,s Ab...Acular® opthalmic solution on the first day f...olac is therapeutically equivalent to Acular®...
(Date:11/6/2009)...IS, November 6 , - Trial ...lid for the,Treatment of Multi-Resistant Staphyloc... a speciality pharmaceutical company focused on th...esigned to overcome the significant global,problem... most advanced oral,antibacterial NXL103 (floprist...
(Date:11/5/2009)...GO, Nov. 5 Althea Technologies, I...turing services for biopharmaceutical products ann...lopment to the company,s platform of services, whi...es Matsuura, Director of Formulation Development. ...ion and analytical scientists, along with new labo...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 1Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 3Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 12721 4Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 1Geographic profiling applied to track hunting patterns of white sharks in South Africa 8945 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 1Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 2Iran Blocks Access to the Chopra Center 26apos 3Bs Web Site Podcasts and Blogs 49586 3
...Company Planning to Initiate Phase 2 Trials in Col...Cancer in Q307 -, SOUTH SAN FRANCISCO, Calif., Jun...aceuticals, Inc. , a,biopharmaceutical company foc...s from an interim safety analysis of two Phase 1,d...ion platinum for,the potential first-line treatmen...
...ven year follow up of pivotal trial confirms that ...EL, Switzerland, June 4, 2007-A follow-up analysis...non-Hodgkin,s lymphoma,(NHL) who were treated with...) over seven years ago has revealed exciting resul...ase III study has shown,that over half (53%) of th...
Other Medicine Technology:Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 2MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 3MabThera Significantly Extends Survival And Cures More Patients,With Aggressive Lymphoma Than Chemotherapy Alone 4
(Date:11/8/2009)...8 Pharmaceutical Resear...e President Ken Johnson released the following sta...: ,, "We are disappointed, but not surprised by...of hardworking Americans as well as nearly half of...who voted against the bill. ,, "While well inte...
(Date:11/8/2009)... Shows Who Sides With Working Families vs. Insuran...swire-USNewswire/ -- On the heels of an historic l... a good, balanced health care reform bill, the Pen...state,s U.S. representatives voted on HR 3962, the...e legislation, which passed Saturday evening by a ...
(Date:11/7/2009)...v. 7 Speaker Nancy Pel....R. 3962, the Affordable Health Care for America A...tonight. Below are the Speaker,s remarks. ,, ...ric moment for our nation and for American familie...nd political philosophy -- as far back as Teddy Ro...
(Date:11/7/2009)...PRNewswire/ -- Calling this a "defining moment" fo...President J. James Rohack, M.D., today addressed m...te and medical specialty societies at the opening ...ere health system reform will top the agenda. ,...81209/AMALOGO ) ,, "Over the next 72 hours, t...
(Date:11/7/2009)...7 The U.S. bishops Nove...es to vote for the Stupak-Ellsworth Amendment to t...-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment ... funding and conscience protections in the Afforda... said. ,, The letter was signed by Cardinal Jus...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
...Alseres Pharmaceuticals, Inc. today announced that...ASDAQ Stock Market ("NASDAQ") that for the last 10... listed securities has been below the minimum $35 ...NASDAQ Marketplace Rule 4310(c)(3)(A) or 4310(c)(3...
...scular group practice to use Sage Intergy solution...ition itself for pay-for-performance , , TAMPA, F...scular Institute, a Saginaw-Mich.-based group prac...(PM) and Sage Intergy EHR electronic health reco...
...eveal targets for future treatments , , MO...they have discovered genes in prostate cancer cell...th each other, an occurrence that may initiate the...cer cells, a finding that may serve as a marker fo...
...an Inc. (Nasdaq: MYL ),today announced that its ...onal U.S. patents protecting the company,s Perforo... pulmonary disease (COPD) treatment. , U.S. Pa...ormoterol. This patent covers Dey,s Perforomist(R)...
...publication of its kind aimed at healthcare fraud ...e Insight(R) (HCI), a Verisk HealthCare company an... and overpayment prevention solutions for healthca...lication dedicated to helping public and private s...
... Boehringer Ingelheim today announced the appoint...Sales and Marketing for the company,s Prescription...ad the U.S. sales and marketing strategy of Boehri...ef Executive Officer, Boehringer Ingelheim Corpora...
Other Medicine News:Health News:Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements 2Health News:Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements 3Health News:Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements 4Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 2Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 3Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 4Health News:Michigan CardioVascular Institute Selects Sage Intergy EHR to Streamline Clinical, Workflow and Reporting Efficiencies 5Health News:U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution 2Health News:HealthCare Insight(R) Launches Industry Fraud Magazine 2Health News:Boehringer Ingelheim Appoints Albert Ros as Executive Vice President of Sales and Marketing for Prescription Medicines 2
RNA1c Control for Bayer DCA 2000 and 2000 + Analyzers
Molteno3 Glaucoma Drainage Device
...s a reagent and probe system used together to quan...t plate based system is a sandwich nucleic acid hy...for RNA detection and quantification, by amplifyin...chnology. Branched DNA allows immediate quantifica...
Cormet Hip Resurfacing System
Medicine Products: